CREBBP and Miyoshi myopathy: The CREBBP/EP300 bromodomain inhibitor inobrodib, currently being tested in combination with pomalidomide and dexamethasone in a phase 1/2a clinical trial for MM (NCT04068597), has shown promising activity, with an overall response rate of 67% reported so far115.